Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKST02 in relapsed or refractory multiple myeloma
NCT06574568Phase 1Recruiting
- Sponsor
- Excyte Biopharma Ltd
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of YKST02 in multiple myeloma (MM), sponsored by Excyte Biopharma Ltd. Primary endpoints: Number of Participants with Dose-limiting Toxicities at 21 days, Incidence of Adverse Events at 42 weeks and 2 more. Started Jun 2024; status: recruiting.
02
Drugs
YKST02
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06574568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06574568.